Stocktoria
PROVECTUS BIOPHARMACEUTICALS, INC. PVCT
OTC · OOTC · stock
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $336,108 at a -1615.8% net margin.
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Net margin-1615.8%
Revenue trend · last 4y · down
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
FAQ
Is PVCT financially healthy?
PROVECTUS BIOPHARMACEUTICALS, INC.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does PVCT pay a dividend?
No, PROVECTUS BIOPHARMACEUTICALS, INC. does not currently pay a dividend.
How profitable is PVCT?
In FY2025, PROVECTUS BIOPHARMACEUTICALS, INC. had a net margin of -1615.8%.
Source: SEC EDGAR filings · CIK 0000315545 · US · as of 2025-12-31. facts plus Stocktoria's own computed scores — not investment advice.